$100M raised to advance canine longevity drug toward FDA reviewFebruary 16, 2026 Biotech company Loyal reports progress on Expanded Conditional Approval requirements and enrollment completion in 1,300-dog STAY trial
SPONSORED CONTENTWhere unique needs meet innovative scienceFind precise, innovative solutions for your patients' unique needs + Learn More
FDA accepts safety data for canine longevity drugJanuary 13, 2026Loyal advances toward market approval with acceptance of Target Animal Safety section for its senior dog lifespan extension drug, LOY-002.
Canine longevity drug advances toward FDA approvalMarch 4, 2025The FDA’s Center for Veterinary Medicine has accepted the Reasonable Expectation of Effectiveness (RXE) for LOY-002. Learn more about what this ‘milestone’ means in the pursuit of an FDA conditional approval.
$45M additional funding bolsters development of canine longevity drugMarch 25, 2024The latest financing round brings the total funds raised for the first FDA-approved dog lifespan extension drug to $125M
